Rapport Therapeutics (RAPP) Treasury Shares (2023 - 2026)
Rapport Therapeutics (RAPP) reported Treasury Shares of $144257.0 for Q1 2026, up 67.73% year-over-year from $86008.0 in Q1 2025, and down 64.97% quarter-over-quarter from $411833.0 in Q4 2025.
Rapport Therapeutics (RAPP) Treasury Shares (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Treasury Shares data on file, last reported at $144257.0 in Q1 2026.
- Treasury Shares for Q1 2026 came in at $144257.0, up 67.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $144257.0 (up 67.73% YoY), and the FY2025 annual result was $411833.0, down 57.83% from the prior year.
- Treasury Shares retreated to $144257.0 in Q1 2026 per RAPP's latest filing, from $411833.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $1.6 million in Q4 2023 and troughed at -$46702.0 in Q3 2023.
- A 4-year average of $641175.9 and a median of $478034.0 in 2025 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2024 and 2025: Treasury Shares jumped 2487.59% in 2024, then slumped 76.42% in 2025.
- A 4-year view of Treasury Shares shows it stood at $1.6 million in 2023, then tumbled by 38.42% to $976596.0 in 2024, then tumbled by 57.83% to $411833.0 in 2025, then tumbled by 64.97% to $144257.0 in 2026.
- Business Quant data shows RAPP's Treasury Shares at $144257.0 in Q1 2026, $411833.0 in Q4 2025, and $544235.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | 144,257.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144,257.00 |
| Mar 31, 2026 | 144,257.00 |
| Dec 31, 2025 | 411,833.00 |
| Dec 31, 2025 | 411,833.00 |
| Sep 30, 2025 | 544,235.00 |
| Sep 30, 2025 | 544,235.00 |
| Jun 30, 2025 | 304,253.00 |
| Jun 30, 2025 | 304,253.00 |
| Mar 31, 2025 | 86,008.00 |
| Mar 31, 2025 | 86,008.00 |
| Dec 31, 2024 | 976,596.00 |
| Dec 31, 2024 | 976,596.00 |
| Sep 30, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | -46,702.00 |
| Sep 30, 2023 | -46,702.00 |